Aneuvo

Executive Summary

Aneuvo is a San Francisco-based medical device company pioneering non-invasive neurotechnology for neurological disorders, with a lead product—the ExaStim Stimulation System—designed to restore motor function in spinal cord injury patients. Founded in 2021, the company leverages transcutaneous spinal stimulation, a non-surgical approach that modulates neural circuits to enable voluntary movement. This technology addresses a significant unmet need, as current treatments for spinal cord injury are limited to physical therapy and invasive implants, leaving many patients with permanent disability. Aneuvo's platform has the potential to improve quality of life for the hundreds of thousands of individuals affected worldwide. As an early-stage private company, Aneuvo is poised to advance through preclinical and early clinical milestones. The ExaStim device offers a less risky, more scalable alternative to traditional neurostimulation, and the company is actively seeking regulatory clearances and funding to support first-in-human studies. If successful, Aneuvo could disrupt the neurorehabilitation market, which is dominated by costly, invasive solutions. Near-term catalysts include pivotal trial initiation, FDA breakthrough designation, and series A financing, which would validate its technology and accelerate commercialization.

Upcoming Catalysts (preview)

• H2 2026Initiation of pivotal clinical trial for ExaStim60% success
• Q3 2026FDA Breakthrough Device Designation70% success
• Q4 2026Series A funding close50% success